Concepts (262)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Child Development | 14 | 2023 | 89 | 2.130 |
Why?
|
| HIV Infections | 27 | 2024 | 4946 | 1.580 |
Why?
|
| Adolescent | 31 | 2024 | 2858 | 1.470 |
Why?
|
| Humans | 64 | 2024 | 14077 | 1.360 |
Why?
|
| Growth Disorders | 4 | 2020 | 56 | 1.330 |
Why?
|
| Child | 27 | 2024 | 2180 | 1.140 |
Why?
|
| Mental Disorders | 4 | 2016 | 40 | 1.140 |
Why?
|
| Family Health | 4 | 2014 | 16 | 1.130 |
Why?
|
| Cognition | 6 | 2021 | 75 | 1.100 |
Why?
|
| Parent-Child Relations | 3 | 2014 | 16 | 1.040 |
Why?
|
| Child Welfare | 4 | 2009 | 16 | 1.020 |
Why?
|
| Child, Preschool | 19 | 2023 | 1675 | 0.980 |
Why?
|
| Child, Orphaned | 5 | 2022 | 16 | 0.970 |
Why?
|
| Female | 40 | 2024 | 8751 | 0.960 |
Why?
|
| Poverty | 4 | 2023 | 149 | 0.940 |
Why?
|
| Government | 1 | 2024 | 13 | 0.910 |
Why?
|
| Research Design | 2 | 2024 | 123 | 0.820 |
Why?
|
| Mental Health | 4 | 2023 | 86 | 0.790 |
Why?
|
| Risk-Taking | 2 | 2019 | 119 | 0.760 |
Why?
|
| Mothers | 5 | 2024 | 190 | 0.760 |
Why?
|
| Male | 27 | 2022 | 6489 | 0.740 |
Why?
|
| South Africa | 24 | 2024 | 7312 | 0.730 |
Why?
|
| Hepatitis B, Chronic | 3 | 2011 | 44 | 0.730 |
Why?
|
| Adolescent, Institutionalized | 1 | 2020 | 1 | 0.700 |
Why?
|
| Child, Institutionalized | 1 | 2020 | 1 | 0.700 |
Why?
|
| Institutionalization | 1 | 2020 | 2 | 0.700 |
Why?
|
| Caregivers | 3 | 2023 | 66 | 0.690 |
Why?
|
| Health Promotion | 5 | 2023 | 108 | 0.680 |
Why?
|
| Anti-HIV Agents | 8 | 2021 | 1275 | 0.680 |
Why?
|
| Mother-Child Relations | 1 | 2020 | 20 | 0.670 |
Why?
|
| Child Health | 1 | 2020 | 76 | 0.660 |
Why?
|
| Hepatitis B virus | 3 | 2011 | 155 | 0.660 |
Why?
|
| Alcohol Drinking | 1 | 2019 | 53 | 0.660 |
Why?
|
| Parenting | 5 | 2024 | 19 | 0.660 |
Why?
|
| Adolescent Behavior | 1 | 2019 | 58 | 0.660 |
Why?
|
| Social Support | 3 | 2024 | 76 | 0.650 |
Why?
|
| Quality of Life | 2 | 2022 | 170 | 0.650 |
Why?
|
| Infant | 12 | 2024 | 2145 | 0.590 |
Why?
|
| Ecology | 1 | 2017 | 5 | 0.580 |
Why?
|
| Adult | 21 | 2024 | 5664 | 0.580 |
Why?
|
| Antiviral Agents | 3 | 2010 | 107 | 0.550 |
Why?
|
| Cohort Studies | 7 | 2023 | 939 | 0.500 |
Why?
|
| Nutritional Status | 1 | 2015 | 75 | 0.480 |
Why?
|
| Child of Impaired Parents | 3 | 2009 | 9 | 0.480 |
Why?
|
| Models, Theoretical | 2 | 2014 | 78 | 0.480 |
Why?
|
| Socioeconomic Factors | 7 | 2019 | 405 | 0.470 |
Why?
|
| Acquired Immunodeficiency Syndrome | 4 | 2014 | 186 | 0.460 |
Why?
|
| HLA Antigens | 2 | 2011 | 50 | 0.450 |
Why?
|
| Infant, Newborn | 6 | 2024 | 1410 | 0.430 |
Why?
|
| Breast Feeding | 2 | 2016 | 119 | 0.410 |
Why?
|
| Epitopes, T-Lymphocyte | 2 | 2011 | 12 | 0.400 |
Why?
|
| Intimate Partner Violence | 2 | 2022 | 52 | 0.390 |
Why?
|
| Infectious Disease Transmission, Vertical | 5 | 2023 | 467 | 0.390 |
Why?
|
| Hepatitis B e Antigens | 1 | 2011 | 26 | 0.380 |
Why?
|
| Child Abuse | 4 | 2022 | 10 | 0.380 |
Why?
|
| Carcinoma, Pancreatic Ductal | 2 | 2022 | 6 | 0.350 |
Why?
|
| Pancreatic Neoplasms | 2 | 2022 | 9 | 0.350 |
Why?
|
| Global Health | 6 | 2020 | 183 | 0.340 |
Why?
|
| Prevalence | 5 | 2020 | 1149 | 0.330 |
Why?
|
| Schools | 3 | 2023 | 67 | 0.310 |
Why?
|
| Africa | 4 | 2023 | 360 | 0.310 |
Why?
|
| Young Adult | 9 | 2024 | 2357 | 0.310 |
Why?
|
| Rural Population | 4 | 2024 | 624 | 0.300 |
Why?
|
| United Nations | 3 | 2023 | 12 | 0.300 |
Why?
|
| Pregnancy Complications, Infectious | 3 | 2023 | 507 | 0.300 |
Why?
|
| Cholagogues and Choleretics | 1 | 2007 | 1 | 0.300 |
Why?
|
| Ursodeoxycholic Acid | 1 | 2007 | 1 | 0.300 |
Why?
|
| Cystic Fibrosis | 1 | 2007 | 9 | 0.300 |
Why?
|
| Liver Diseases | 1 | 2007 | 18 | 0.300 |
Why?
|
| Family Characteristics | 1 | 2008 | 133 | 0.300 |
Why?
|
| Pregnancy | 9 | 2024 | 1815 | 0.280 |
Why?
|
| Developing Countries | 3 | 2022 | 385 | 0.280 |
Why?
|
| Genetic Variation | 1 | 2008 | 169 | 0.270 |
Why?
|
| Pregnant Women | 2 | 2024 | 89 | 0.270 |
Why?
|
| HIV Seropositivity | 1 | 2009 | 263 | 0.270 |
Why?
|
| Ribavirin | 1 | 2006 | 15 | 0.270 |
Why?
|
| Interferon-alpha | 1 | 2006 | 15 | 0.270 |
Why?
|
| Drug Costs | 1 | 2006 | 18 | 0.260 |
Why?
|
| Hepacivirus | 1 | 2006 | 37 | 0.260 |
Why?
|
| Infectious Disease Transmission, Patient-to-Professional | 1 | 2006 | 11 | 0.260 |
Why?
|
| Health Services Accessibility | 7 | 2023 | 265 | 0.260 |
Why?
|
| Hepatitis C, Chronic | 1 | 2006 | 26 | 0.260 |
Why?
|
| Cross Infection | 1 | 2006 | 49 | 0.250 |
Why?
|
| Mutation | 3 | 2022 | 299 | 0.250 |
Why?
|
| Anti-Retroviral Agents | 5 | 2021 | 542 | 0.240 |
Why?
|
| Celiac Artery | 1 | 2004 | 1 | 0.240 |
Why?
|
| Ligaments | 1 | 2004 | 1 | 0.240 |
Why?
|
| Abdominal Pain | 1 | 2004 | 7 | 0.240 |
Why?
|
| Running | 1 | 2004 | 6 | 0.240 |
Why?
|
| Arterial Occlusive Diseases | 1 | 2004 | 9 | 0.240 |
Why?
|
| Sexual Behavior | 3 | 2022 | 313 | 0.240 |
Why?
|
| Prospective Studies | 4 | 2020 | 1131 | 0.240 |
Why?
|
| Africa South of the Sahara | 2 | 2020 | 328 | 0.230 |
Why?
|
| Antiretroviral Therapy, Highly Active | 2 | 2010 | 468 | 0.230 |
Why?
|
| Cost-Benefit Analysis | 2 | 2024 | 235 | 0.230 |
Why?
|
| Pandemics | 2 | 2023 | 280 | 0.230 |
Why?
|
| Health Personnel | 1 | 2006 | 229 | 0.220 |
Why?
|
| Social Work | 1 | 2023 | 2 | 0.220 |
Why?
|
| Pre-Exposure Prophylaxis | 2 | 2016 | 171 | 0.210 |
Why?
|
| Delivery of Health Care | 2 | 2024 | 230 | 0.210 |
Why?
|
| Policy Making | 1 | 2023 | 30 | 0.210 |
Why?
|
| Communicable Disease Control | 1 | 2023 | 101 | 0.200 |
Why?
|
| Urban Population | 1 | 2024 | 246 | 0.200 |
Why?
|
| Problem Behavior | 1 | 2022 | 6 | 0.200 |
Why?
|
| Behavior Therapy | 1 | 2021 | 11 | 0.200 |
Why?
|
| Resilience, Psychological | 2 | 2014 | 11 | 0.200 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 2 | 2022 | 7 | 0.190 |
Why?
|
| Health Services | 1 | 2021 | 44 | 0.190 |
Why?
|
| House Calls | 1 | 2021 | 8 | 0.190 |
Why?
|
| Cross-Sectional Studies | 5 | 2024 | 1377 | 0.190 |
Why?
|
| Molecular Sequence Data | 3 | 2011 | 263 | 0.190 |
Why?
|
| Crime Victims | 1 | 2020 | 5 | 0.180 |
Why?
|
| Sex Offenses | 1 | 2020 | 29 | 0.180 |
Why?
|
| Asia, Central | 1 | 2020 | 1 | 0.170 |
Why?
|
| Far East | 1 | 2020 | 1 | 0.170 |
Why?
|
| Orphanages | 1 | 2020 | 2 | 0.170 |
Why?
|
| Africa, Northern | 1 | 2020 | 5 | 0.170 |
Why?
|
| Residential Facilities | 1 | 2020 | 3 | 0.170 |
Why?
|
| North America | 1 | 2020 | 11 | 0.170 |
Why?
|
| Latin America | 1 | 2020 | 10 | 0.170 |
Why?
|
| Middle East | 1 | 2020 | 8 | 0.170 |
Why?
|
| Europe | 1 | 2020 | 53 | 0.170 |
Why?
|
| Asia | 1 | 2020 | 70 | 0.170 |
Why?
|
| Social Determinants of Health | 1 | 2019 | 11 | 0.170 |
Why?
|
| Violence | 1 | 2020 | 68 | 0.170 |
Why?
|
| Amino Acid Sequence | 2 | 2011 | 139 | 0.170 |
Why?
|
| Inflammatory Bowel Diseases | 1 | 2019 | 4 | 0.170 |
Why?
|
| Immunologic Factors | 1 | 2019 | 9 | 0.160 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2019 | 44 | 0.160 |
Why?
|
| Health Status | 1 | 2020 | 111 | 0.160 |
Why?
|
| Qualitative Research | 1 | 2019 | 294 | 0.150 |
Why?
|
| Randomized Controlled Trials as Topic | 3 | 2024 | 237 | 0.150 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2017 | 11 | 0.140 |
Why?
|
| Age Factors | 2 | 2008 | 364 | 0.140 |
Why?
|
| Costs and Cost Analysis | 2 | 2008 | 41 | 0.140 |
Why?
|
| Biomarkers, Tumor | 1 | 2017 | 25 | 0.140 |
Why?
|
| Executive Function | 1 | 2016 | 23 | 0.130 |
Why?
|
| Antibodies, Monoclonal | 1 | 2017 | 137 | 0.130 |
Why?
|
| Retrospective Studies | 3 | 2022 | 767 | 0.130 |
Why?
|
| Drug Therapy, Combination | 3 | 2019 | 271 | 0.130 |
Why?
|
| Middle Aged | 4 | 2019 | 3425 | 0.120 |
Why?
|
| Risk Factors | 4 | 2022 | 1431 | 0.120 |
Why?
|
| Mass Screening | 1 | 2016 | 242 | 0.120 |
Why?
|
| Child Nutrition Disorders | 1 | 2014 | 10 | 0.120 |
Why?
|
| Internationality | 1 | 2014 | 34 | 0.120 |
Why?
|
| Child Abuse, Sexual | 1 | 2014 | 4 | 0.110 |
Why?
|
| United States | 1 | 2014 | 129 | 0.110 |
Why?
|
| Developmental Disabilities | 1 | 2014 | 22 | 0.110 |
Why?
|
| Health Services Needs and Demand | 3 | 2010 | 57 | 0.110 |
Why?
|
| Follow-Up Studies | 2 | 2021 | 367 | 0.110 |
Why?
|
| Child Health Services | 1 | 2013 | 33 | 0.110 |
Why?
|
| Health Resources | 1 | 2013 | 65 | 0.110 |
Why?
|
| Health Care Costs | 1 | 2013 | 107 | 0.100 |
Why?
|
| Stress, Psychological | 2 | 2010 | 25 | 0.100 |
Why?
|
| Surveys and Questionnaires | 3 | 2024 | 532 | 0.100 |
Why?
|
| Adaptation, Biological | 1 | 2011 | 5 | 0.100 |
Why?
|
| China | 1 | 2011 | 21 | 0.100 |
Why?
|
| Depression | 2 | 2024 | 117 | 0.100 |
Why?
|
| Australia | 1 | 2011 | 46 | 0.100 |
Why?
|
| Host-Pathogen Interactions | 1 | 2011 | 24 | 0.100 |
Why?
|
| Malaria | 1 | 2014 | 207 | 0.100 |
Why?
|
| Polymorphism, Genetic | 1 | 2011 | 96 | 0.090 |
Why?
|
| Phylogeny | 1 | 2011 | 231 | 0.090 |
Why?
|
| Patient Rights | 1 | 2010 | 3 | 0.090 |
Why?
|
| Medication Adherence | 2 | 2021 | 137 | 0.090 |
Why?
|
| Genome, Viral | 1 | 2010 | 64 | 0.090 |
Why?
|
| Sequence Analysis, DNA | 1 | 2010 | 180 | 0.080 |
Why?
|
| Malawi | 2 | 2023 | 86 | 0.080 |
Why?
|
| Adaptation, Psychological | 1 | 2009 | 26 | 0.080 |
Why?
|
| Tanzania | 2 | 2022 | 84 | 0.080 |
Why?
|
| Vulnerable Populations | 1 | 2008 | 30 | 0.080 |
Why?
|
| Quality Assurance, Health Care | 1 | 2009 | 43 | 0.080 |
Why?
|
| Social Perception | 1 | 2008 | 7 | 0.080 |
Why?
|
| Tuberculosis | 1 | 2014 | 530 | 0.080 |
Why?
|
| Patient Education as Topic | 1 | 2008 | 48 | 0.080 |
Why?
|
| Hypertension, Portal | 1 | 2007 | 1 | 0.070 |
Why?
|
| Liver Function Tests | 1 | 2007 | 3 | 0.070 |
Why?
|
| Educational Status | 2 | 2021 | 68 | 0.070 |
Why?
|
| Human Rights | 1 | 2008 | 12 | 0.070 |
Why?
|
| World Health Organization | 1 | 2008 | 134 | 0.070 |
Why?
|
| Residence Characteristics | 1 | 2008 | 56 | 0.070 |
Why?
|
| Longitudinal Studies | 2 | 2022 | 409 | 0.070 |
Why?
|
| Disease Progression | 1 | 2007 | 154 | 0.070 |
Why?
|
| HIV-1 | 2 | 2021 | 1239 | 0.070 |
Why?
|
| Severity of Illness Index | 1 | 2007 | 243 | 0.070 |
Why?
|
| Organometallic Compounds | 1 | 2006 | 3 | 0.070 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2006 | 10 | 0.070 |
Why?
|
| Genotype | 1 | 2008 | 430 | 0.070 |
Why?
|
| Peptides | 1 | 2006 | 40 | 0.070 |
Why?
|
| Polyethylene Glycols | 1 | 2006 | 48 | 0.070 |
Why?
|
| Recombinant Proteins | 1 | 2006 | 72 | 0.070 |
Why?
|
| Clinical Trials as Topic | 1 | 2006 | 112 | 0.060 |
Why?
|
| Treatment Outcome | 1 | 2007 | 867 | 0.060 |
Why?
|
| Syndrome | 1 | 2004 | 19 | 0.060 |
Why?
|
| RNA, Viral | 1 | 2006 | 303 | 0.060 |
Why?
|
| Nutritional Support | 1 | 2024 | 5 | 0.060 |
Why?
|
| Standard of Care | 1 | 2024 | 28 | 0.060 |
Why?
|
| Depression, Postpartum | 1 | 2024 | 22 | 0.060 |
Why?
|
| Postpartum Period | 1 | 2024 | 78 | 0.060 |
Why?
|
| Altruism | 1 | 2023 | 7 | 0.060 |
Why?
|
| Health Facilities | 1 | 2024 | 39 | 0.060 |
Why?
|
| Interdisciplinary Studies | 1 | 2023 | 4 | 0.050 |
Why?
|
| Protective Factors | 1 | 2023 | 7 | 0.050 |
Why?
|
| Probability | 1 | 2023 | 27 | 0.050 |
Why?
|
| Employment | 1 | 2022 | 27 | 0.050 |
Why?
|
| Child Behavior | 1 | 2022 | 11 | 0.050 |
Why?
|
| Models, Statistical | 1 | 2022 | 53 | 0.050 |
Why?
|
| Africa, Southern | 1 | 2021 | 89 | 0.050 |
Why?
|
| Aged | 1 | 2006 | 1650 | 0.050 |
Why?
|
| Medical History Taking | 1 | 2021 | 6 | 0.050 |
Why?
|
| Uganda | 1 | 2021 | 194 | 0.050 |
Why?
|
| Biomarkers | 1 | 2022 | 322 | 0.050 |
Why?
|
| Mozambique | 1 | 2021 | 52 | 0.050 |
Why?
|
| Language Development | 1 | 2020 | 4 | 0.040 |
Why?
|
| Condoms | 1 | 2021 | 86 | 0.040 |
Why?
|
| Body Height | 1 | 2020 | 51 | 0.040 |
Why?
|
| Adalimumab | 1 | 2019 | 1 | 0.040 |
Why?
|
| Infliximab | 1 | 2019 | 2 | 0.040 |
Why?
|
| Victoria | 1 | 2019 | 2 | 0.040 |
Why?
|
| Benchmarking | 1 | 2018 | 10 | 0.040 |
Why?
|
| Treatment Failure | 1 | 2019 | 175 | 0.040 |
Why?
|
| Tertiary Care Centers | 1 | 2019 | 78 | 0.040 |
Why?
|
| Viral Load | 1 | 2021 | 808 | 0.040 |
Why?
|
| Mice, Inbred NOD | 1 | 2017 | 1 | 0.040 |
Why?
|
| Endoscopic Ultrasound-Guided Fine Needle Aspiration | 1 | 2017 | 1 | 0.040 |
Why?
|
| Mice, SCID | 1 | 2017 | 4 | 0.040 |
Why?
|
| Blotting, Western | 1 | 2017 | 14 | 0.040 |
Why?
|
| Tumor Cells, Cultured | 1 | 2017 | 20 | 0.040 |
Why?
|
| Immunoenzyme Techniques | 1 | 2017 | 21 | 0.040 |
Why?
|
| Cell Proliferation | 1 | 2017 | 43 | 0.040 |
Why?
|
| Gene Expression Profiling | 1 | 2017 | 41 | 0.030 |
Why?
|
| Neoplasm Staging | 1 | 2017 | 48 | 0.030 |
Why?
|
| Apoptosis | 1 | 2017 | 39 | 0.030 |
Why?
|
| Health Care Surveys | 1 | 2016 | 30 | 0.030 |
Why?
|
| Survival Rate | 1 | 2017 | 96 | 0.030 |
Why?
|
| Antineoplastic Agents | 1 | 2017 | 61 | 0.030 |
Why?
|
| Mice | 1 | 2017 | 134 | 0.030 |
Why?
|
| Prognosis | 1 | 2017 | 197 | 0.030 |
Why?
|
| Students | 1 | 2016 | 48 | 0.030 |
Why?
|
| Administration, Oral | 1 | 2015 | 113 | 0.030 |
Why?
|
| Social Environment | 1 | 2014 | 10 | 0.030 |
Why?
|
| Health Surveys | 1 | 2014 | 59 | 0.030 |
Why?
|
| Animals | 1 | 2017 | 1063 | 0.030 |
Why?
|
| Sex Distribution | 1 | 2014 | 89 | 0.030 |
Why?
|
| Substance-Related Disorders | 1 | 2014 | 49 | 0.030 |
Why?
|
| International Cooperation | 1 | 2014 | 50 | 0.030 |
Why?
|
| Program Development | 1 | 2013 | 32 | 0.030 |
Why?
|
| Odds Ratio | 1 | 2014 | 132 | 0.030 |
Why?
|
| Zimbabwe | 1 | 2014 | 115 | 0.030 |
Why?
|
| Patient Compliance | 1 | 2014 | 120 | 0.030 |
Why?
|
| Capacity Building | 1 | 2013 | 32 | 0.030 |
Why?
|
| Healthcare Disparities | 1 | 2013 | 41 | 0.030 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2014 | 247 | 0.020 |
Why?
|
| CD4 Lymphocyte Count | 1 | 2013 | 654 | 0.020 |
Why?
|
| Protein Precursors | 1 | 2010 | 22 | 0.020 |
Why?
|
| Hunger | 1 | 2010 | 2 | 0.020 |
Why?
|
| Hepatitis B Surface Antigens | 1 | 2010 | 47 | 0.020 |
Why?
|
| Family Relations | 1 | 2010 | 7 | 0.020 |
Why?
|
| Personal Satisfaction | 1 | 2010 | 16 | 0.020 |
Why?
|
| Malnutrition | 1 | 2010 | 53 | 0.020 |
Why?
|
| Financial Support | 1 | 2009 | 10 | 0.020 |
Why?
|
| Income | 1 | 2009 | 83 | 0.020 |
Why?
|